The combination study with TH-302 plus pazopanib was conducted in 30 patients with a variety of solid tumors for whom standard therapy or palliative measures were nonexistent or no longer effective. The clinical benefit rate was 76% (n=25 evaluable patients) with three patients with partial responses (12%) and 16 patients with stable disease (64%). The partial responses were observed in patients with neuroendocrine cancer, ovarian cancer, and chondrosarcoma.
76 percent clinical benefit rate with 64 percent of mostly terminal patients reaching stable disease. The great news keeps on coming in and the stock price stays the same . Red on a daily basis, but not going down. Games games and more games.
I think it's simply a matter of investment in THLD as dead money-- (until, one day, it's not).
It's that simple..
It's not only MM games. Some of the retail investors are getting impatient and are moving on.
However, when it finally takes off, it'll be fast.
I agree--that the stock is range-bound a there are not any significant catalysts that will move this one over the near-term. The dozen analysts would cover the company barely comment on it all these days----though they have commented on the pending '14 sarcoma results. Phase 1 studies don't bring in significant investors who can move the dial, especially when there are so many others in the biotech sector that have more identifiable investment triggers.